Anti-glomerular basement membrane antibody disease treated with rituximab: A case-based review

Seminars in Arthritis and Rheumatism

Volumn 42, Issue 6, 2013, Pages 567-572

  Syeda, Uzma A ^a   Singer, Nora G ^a   Magrey, Marina ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Anti GBM disease; Rituximab

Indexed keywords

ACICLOVIR; AUTOANTIBODY; CYCLOPHOSPHAMIDE; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYELOPEROXIDASE ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE KIDNEY FAILURE; AGED; ANEMIA; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; CLINICAL FEATURE; CONVALESCENCE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENITAL HERPES; GLOMERULONEPHRITIS; GLOMERULUS BASEMENT MEMBRANE; GOODPASTURE SYNDROME; HEMODIALYSIS; HUMAN; KIDNEY BIOPSY; LEUKOPENIA; PLASMAPHERESIS; PRIORITY JOURNAL; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

AGED; ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY GLOMERULUS; PLASMAPHERESIS; PREDNISONE; TREATMENT OUTCOME;

EID: 84881239258     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2012.10.007     Document Type: Article

References (34)

1. Wilson C.B., Dixon F.J. Anti-glomerular basement membrane antibody induced glomerulonephritis. Kidney Int 1973, 3:74-89.
2. Bolton W.K. Good pasture's syndrome. Kidney Int 1996, 50:1753-1766.
3. Salama A.D., Levy J.B., Lightstone L., Pusey C.D. Goodpasture's disease. Lancet 2001, 358:917-920.
4. Peto P., Salama A.D. Update on antiglomerular basement membrane disease. Curr Opin Rheumatol 2011, 23:32-37.
5. Stanton M.C., Tange J.D. Goodpasture's syndrome (pulmonary haemorrhage associated with glomerulonephritis). Australas Ann Med 1958, 7:132-144.
6. Saus J., Wieslander J., Langeveld J.P., Quinones S., Hudson B.G. Identification of the Goodpasture antigen as the alpha 3(IV) chain of collagen IV. J Biol Chem 1988, 263:13374-13380.
7. Lerner R.A., Glassock R.J., Dixon F.J. The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Am Soc Nephrol 1999, 10:1389-1404.
8. Cui Z., Zhao J., Jia X.Y., Zhu S.N., Zhao M.H. Clinical features and outcomes of anti-glomerular basement membrane disease in older patients. Am J Kidney Dis 2011, 57:575-582.
9. Levy J.B., Turner A.N., Rees A.J., Pusey C.D. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001, 134:1033-1042.
10. Cui Z., Zhao J., Jia X.Y., Zhu S.N., Jin Q.Z., Cheng X.Y., et al. Anti-glomerular basement membrane disease: outcomes of different therapeutic regimens in a large single-center Chinese cohort study. Medicine (Baltimore) 2011, 90:303-311.
11. Arzoo K., Sadeghi S., Liebman H.A. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 2002, 61:922-924.
12. Wechsler E., Yang T., Jordan S.C., Vo A., Nast C.C. Anti-glomerular basement membrane disease in an HIV-infected patient. Nat Clin Pract Nephrol 2008, 4:167-171.
13. Shah Y., Mohiuddin A., Sluman C., Daryanani I., Ledson T., Banerjee A., et al. Rituximab in anti-glomerular basement membrane disease. Q J Med 2012, 105:195-197.
14. Kalluri R., Wilson C.B., Weber M., Gunwar S., Chonko A.M., Neilson E.G., et al. Identification of the alpha 3 chain of type IV collagen as the common auto antigen in antibasement membrane disease and Goodpasture syndrome. J Am Soc Nephrol 1995, 6:1178-1185.
15. Hellmark T., Segelmark M., Wieslander J. Anti-GBM antibodies in Goodpasture syndrome; anatomy of an epitope. Nephrol Dial Transplant 1997, 12:646-648.
16. Hudson B.G., Tryggvason K., Sundaramoorthy M. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 2003, 348:2543-2556.
17. Pedchenko V., Bondar O., Fogo A.B., et al. Molecular architecture of the Goodpasture autoantigen in anti-GBMnephritis. N Engl J Med 2010, 363:343-354.
18. Meyers K.E., Christensen M., Madaio M.P. Modeling of human anti-GBMantibody-alpha3(IV)NC1 interactions predict antigenic cross-linking through contact of both heavy chains with repeating epitopes on alpha3(IV)NC1. Am J Nephrol 2009, 30:474-480.
19. Wilson C.B., Dixon F.J. Antiglomerular basement membrane antibody-induced glomerulonephritis. Kidney Int 1973, 3:74-89.
20. Ooi J.D., Holdsworth S.R., Kitching A.R. Advances in the pathogenesis of Goodpasture's disease: from epitopes to autoantibodies to effector T cells. J Autoimmun 2008, 31:295-300.
21. Derry C.J., Ross C.N., Lombardi G., Mason P.D., Rees A.J., Lechler R.I., et al. Analysis of T cell responses to the autoantigen in Goodpasture's disease. Clin Exp Immunol 1995, 100:262-268.
22. Salama A.D., Chaudhry A.N., Ryan J.J., Eren E., Levy J.B., Pusey C.D., et al. In Goodpasture's disease, CD4(+) T cells escape thymic deletion and are reactive with the autoantigen alpha3(IV)NC1. J Am Soc Nephrol 2001, 12(9):1908-1915.
23. Wu J., Hicks J., Borillo J., Glass W.F., Lou Y.H. CD4({thorn}) T cells specific to a glomerular basement membrane antigen mediates glomerulonephritis. J Clin Invest 2002, 109:517-524.
24. Wolf D., Hochegger K., Wolf A.M., Rumpold H.F., Gastl G., Tilg H., et al. CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice. J Am Soc Nephrol 2005, 16:1360.
25. Robertson J., Wu J., Arends J., Glass W., Southwood S., Sette A., et al. Characterization of the T-cell epitope that causes anti-GBM glomerulonephritis. Kidney Int 2005, 68:1061.
26. Fisher M., Pusey C.D., Vaughan R.W., Rees A.J. Susceptibility to anti-glomerular basement membrane disease is strongly associated with HLA-DRB1 genes. Kidney Int 1997, 51:222-229.
27. Hellmark T., Niles J.L., Collins A.B., McCluskey R.T., Brunmark C. Comparison of anti GBM antibodies in sera with or without ANCA. J Am Soc Nephrol 1997, 8:376-385.
28. Levy J.B., Hammad T., Coulthart A., Dougan T., Pusey C.D. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 2004, 66:1535-1540.
29. Lindic J., Vizjak A., Ferluga D., et al. Clinical outcome of patients with coexistent antineutrophil cytoplasmic antibodies and antibodies against glomerular basement membrane. Ther Apher Dial 2009, 13:278-281.
30. Lionaki Sofia, Jennette J.Charles, Falk Ronald J Anti-neutrophil cytoplasmic (ANCA) and anti-glomerular basement membrane (GBM) autoantibodies in necrotizing and crescentic glomerulonephritis. Semin Immunopathol 2007, 29:459-474.
31. Segelmark M., Hellmark T., Wieslander J. The prognostic significance in Goodpasture's disease of specificity, titre and affinity of anti-glomerular- basement-membrane antibodies. Nephron Clin Pract 2003, 94:c59-c68.
32. Herody M., Bobrie G., Gouarin C., Grunfeld J.P., Noel L.H. Anti-GBM disease: predictive value of clinical, histological and serological data. Clin Nephrol 1993, 40:249-255.
33. Watanabe H., Kitagawa W., Suzuki K., Yoshino M., Aoyama R., Miura N., et al. Thrombotic thrombocytopenic purpura in a patient with rapidly progressive glomerulonephritis with both anti-glomerular basement membrane antibodies and myeloperoxidase anti-neutrophil cytoplasmic antibodies. Clin Exp Nephrol 2010, 14:598-601.
34. Torok N., Niazi M., Al Ahwel Y., Taleb M., Taji J., Assaly R. Thrombotic thrombocytopenic purpura associated with anti-glomerular basement membrane disease. Nephrol Dial Transplant 2010, 25:3446-3449.